Weekly shot could help shed pounds in obesity trial

NCT ID NCT07690826

Not yet recruiting Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This phase 2 study tests HRS-4729, a once-weekly injection, for weight loss in adults with obesity who do not have diabetes. About 252 participants will receive either the drug or a placebo. The main goal is to see how much body weight changes after 32 weeks compared to a placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-4729 injection
What this could lead to: If successful, this could offer a new once-weekly injection to help people with obesity lose significant weight.
What could go wrong: This is an early phase 2 trial, so the drug may not prove effective or safe enough for wider use. Side effects are possible, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.